Document is current
Any future updates will be listed below
-
Authors
Lindauer, Markus
Reissfelder, Florian
Hegenbart, Ute https://orcid.org/0000-0003-1917-6746
Luft, Thomas https://orcid.org/0000-0002-0387-1640
Martens, Uwe M. https://orcid.org/0000-0001-7999-4359
Dreger, Peter https://orcid.org/0000-0002-7429-8570
- License Information
-
More Information
Article History
Received: 13 August 2025
Revised: 3 October 2025
Accepted: 7 November 2025
First Online: 15 November 2025
Competing interests
: UH reports honorarium for talks: Janssen, Pfizer, Alnylam, Akcea, Prothena, Astra Zeneca; financial support of congress participation: Janssen, Prothena, Pfizer; advisory boards: Pfizer, Prothena, Janssen, Alexion; financial sponsoring of Amyloidosis Registry: Janssen. PD reports consultancy for AbbVie, AstraZeneca, Beigene, BMS, Gilead, Miltenyi (all to institution); speakers bureau for AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Riemser, Roche (all to institution); research support from Riemser (all to institution); meeting attendance support from Beigene and Gilead; Participation on a Data Safety Monitoring Board for Novartis. The remaining authors declare no competing financial interests.
